Related Experiment Videos
Pentastarch may cause fewer effects on coagulation than hetastarch
R G Strauss1, C Stansfield, R A Henriksen
1Department of Pathology, University of Iowa College of Medicine, Elmer L. DeGowin Memorial Blood Center, University of Iowa Hospitals and Clinics, Iowa City.
Transfusion
|May 1, 1988
Summary
Pentastarch, a new hydroxyethyl starch analog, shows fewer negative effects on blood coagulation compared to hetastarch. This suggests pentastarch may offer greater safety for patients needing plasma volume expansion.
Area of Science:
- Biochemistry
- Hematology
- Pharmacology
Background:
- Hetastarch (HES) is a widely used plasma volume expander.
- HES administration is associated with significant alterations in hemostasis.
- The precise hemostatic effects of HES and its analogs require further investigation.
Purpose of the Study:
- To compare the effects of pentastarch, a novel HES analog, with hetastarch on blood coagulation.
- To evaluate the safety profile of pentastarch in comparison to hetastarch.
Main Methods:
- Comparative analysis of coagulation parameters in vitro.
- Assessment of bleeding times and clotting factor levels.
- Evaluation of thrombin and clot lysis times.
Main Results:
- Pentastarch demonstrated lesser effects on coagulation assays compared to hetastarch, even at similar plasma concentrations.
- Pentastarch showed minimal impact on factor VIII levels and bleeding times.
- Unlike hetastarch, pentastarch did not affect urokinase-activated clot lysis time.
Conclusions:
- Pentastarch exhibits a more favorable hemostatic profile than hetastarch.
- Pentastarch may be a safer alternative for plasma volume expansion, particularly in patients with pre-existing bleeding risks.
- Further clinical studies are warranted to confirm the safety and efficacy of pentastarch.